PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on two of the world’s most challenging conditions – Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor / Ataxia (FXTAS). There are no FDA approved treatments for the core symptoms of ASD and no FDA approved treatments at all for FXTAS. We exist in order to change that.
We are continuing to pursue opportunities to license or acquire additional late stage assets and are dedicated to collaborating with companies, academia, patient advocacy groups, and other industry stakeholders worldwide. If you are interested in a partnership with PaxMedica, please contact us at firstname.lastname@example.org.
For patients needing more information, please contact: